Abliva AB

Abliva AB

Health CarePharmaceuticals and Biotechnology
  • Price (SEK)0.1786
  • Today's Change-0.004 / -2.30%
  • Shares traded545.74k
  • 1 Year change-67.94%
  • Beta1.1106
Data delayed at least 15 minutes, as of Sep 29 2022 15:25 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Events & Activity

  • ABLI:STO price reached a new 52-week low of 0.175 at 13:52 BST
  • ABLI:STO price reached a new 52-week low of 0.176 at 13:52 BST
  • ABLI:STO price moved over +5.67% to 0.19
  • ABLI:STO trading volume exceeds daily average by +21.69%

Key statistics

Abliva AB (ABLI:STO) set a new 52-week low during Wednesday's trading session when it reached 0.1744. Over this period, the share price is down -68.60%.
52-week range
0.1744Sep 28 20220.7416Jan 14 2022
Markit short selling activity
Previous close0.1828
Average volume1.84m
Shares outstanding1.06bn
Free float1.05bn
P/E (TTM)--
Market cap189.92m SEK
EPS (TTM)-0.2717
Data delayed at least 15 minutes, as of Sep 29 2022 15:25 BST.
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.